We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » OTSUKA INTRODUCES ABILIFY IN JAPAN

OTSUKA INTRODUCES ABILIFY IN JAPAN

June 8, 2006

Japan's Otsuka Pharmaceutical has introduced an atypical antipsychotic agent, Abilify, in the country. Abilify was approved for marketing in the U.S. as a treatment for schizophrenia in November 2002, and is currently marketed in more than 45 countries and regions, including Europe.

"For more than half a century, antipsychotics have provided an effective means for the treatment of schizophrenia," said Kunitoshi Kamijima, a professor at the International University of Health and Welfare. "However, both patients and physicians have continued to be distressed by adverse reactions such as muscle rigidity, finger tremors and mask-like facial expressions that are due to extrapyramidal symptoms Clinicians have high expectations for Abilify, with dopamine partial agonist action, which broadens the options for the treatment of schizophrenia."

Abilify works as a partial agonist against dopamine D2 receptors and differs from other antipsychotics in this respect. It has shown inhibitory action when large amounts of dopamine are released in the brain and stimulatory action when only small amounts of dopamine are released. Because of this mechanism of action, the drug is known as a dopamine system stabilizer, meaning that it improves both positive and negative symptoms of schizophrenia considered to be caused by dopamine abnormalities.

KEYWORDS Daily International Pharma Alert

Upcoming Events

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

  • 10Aug

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

  • FDA Warns Baby Neck Floats Used in Water Therapy Can Cause Death or Injury

  • U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing